Depression in the Context of Cancer

Biology of Depression: From Novel Insights to Therapeutic Strategies

Volumn , Issue , 2008, Pages 365-385

  Coups, Elliot J ^a   Winell, Jeremy ^a   Holland, Jimmie C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer; Cytokines; Diagnosis; Measurement; Suggestions

Indexed keywords

EID: 84891005228     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527619672.ch14     Document Type: Chapter

References (84)

1. Rifkin, a., Reardon, G., Siris, s., et al., Trimipramine in physical illness with depression. J. Clin. Psychiatry 1985, 46, 4-8.
2. Bukberg, j., Penman, D., Holland, j. C., Depression in hospitalized cancer patients. Psychosom. Med. 1984, 46, 199-212.
3. Spitzer, R. L., Williams, j., Gibbons, M., First, M. B., Structured Clinical Interview for DSM-III-R (SCID). Users Guide for the Structured Clinical Interview for DSM-III-R. Washington, DC: American Psychiatric Press, 1990.
4. Endicott, j., Measurement of depression in patients with cancer. Cancer 1984, 53, 2243-2248.
5. Rapp, S. R., Vrana, S., Substituting nonsomatic for somatic symptoms in the diagnosis of depression in elderly male medical patients. Am. J. Psychiatry 1989, 146, 1197-1200.
6. Cohen-Cole, S. A., Brown, F. W., McDaniel, j. S., Diagnostic assessment of depression in the medically ill. In: Stoudemire, A., Fogel, B. S. (Eds.), Psychiatric Care of the Medical Patient. New York: Oxford University Press, 1993, 53-70.
7. Raison, C. L., Miller, A. H., Depression in cancer: New developments regarding diagnosis and treatment. Biol. Psychiatry 2003, 54, 283-294.
8. Yirmiya, R., Weidenfeld, j., Poliak, Y., et al., Cytokines, "depression due to a medical condition," and antidepressant drugs. Adv. Exp. Med. Biol. 1999, 461, 283-316.
9. Chochinov, H. M., Wilson, K. G., Enns, M., Lander, S., Prevalence of depression in the terminally ill: Effects of diagnostic criteria and symptom threshold judgments. Am. J. Psychiatry 1994, 151, 537-540.
10. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994.
11. Spitzer, R. L., Endicott, j., Robins, E., Research Diagnostic Criteria: Rationale and reliability. Arch. Gen. Psychiatry 1978, 35, 773-782.
12. First, M. B., Spitzer, R. L., Gibbon, M., Williams, j. B. W., Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute, 2002.
13. First, M. B., Spitzer, R. L., Gibbon, M., Williams, j. B. W., Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press, Inc., 1996.
14. Endicott, j., Spitzer, R. L., A diagnostic interview: The Schedule for Affective Disorders and Schizophrenia. Arch. Gen. Psychiatry 1978, 35, 837-844.
15. Spitzer, R. L., Williams JBW, Kroenke, K., et al., Utility of a new procedure for diagnosing mental disorders in primary care: The PRIME-MD 1000 study. JAMA 1994, 272, 1749-1756.
16. Robins, L. N., Helzer, J. E., Croughan, J., Ratcliff, K. F., National Institute of Mental Health Diagnostic Interview Schedule: Its history, characteristics, and validity. Arch. Gen. Psychiatry 1981, 38, 381-389.
17. Beck, A. T., Brown, G., Steer, R. A., Beck Depression Inventory II Manual. San Antonio, TX: The Psychological Corporation, 1996.
18. Zigmond, A. S., Snaith, R. p., The Hospital Anxiety and Depression Scale. Acta Psychiatr. Scand. 1983, 67, 361-370.
19. Carroll, B. J., Feinberg, M., Smouse, p. E., Rawson, S. G., Greden, J. F., The Carroll rating scale for depression I, Development, reliability, and validation. Br. J. Psychiatry 1981, 138, 194-200.
20. Wilson, K. G., Chochinov, H. M., de Faye, B. J., Breitbart, W., Diagnosis and management of depression in palliative care. In: Chochinov, H. M., Breitbart, W. (Eds.), Handbook of Psychiatry in Palliative Medicine. New York: Oxford University Press, 2000, 25-49.
21. Roth, A. J., Holland, J. C., Treatment of depression in cancer patients. Prim. Care Cancer 1994, 14, 23-29.
22. Potash, M., Breitbart, W., Affective disorders in advanced cancer. Hematol. Oncol. Clin. North Am. 2002, 16, 671-700.
23. Chochinov, H. M., Wilson, K. G., Enns, M., Lander, S., "Are you depressed?" Screening for depression in the terminally ill. Am. J. Psychiatry 1997, 154, 674-676.
24. Massie, M. J., Prevalence of depression in patients with cancer. J. Natl. Cancer Inst. Monogr. 2004, 32, 57-71.
25. McDaniel, J. S., Musselman, D. L., Porter, M. R., Reed, D. A., Nemeroff, C. B., Depression in patients with cancer: Diagnosis, biology, and treatment. Arch. Gen. Psychiatry 1995, 52, 89-99.
26. Blazer, D. G., Kessler, R. C., McGonagle, K. A., Swartz, M. S., The prevalence and distribution of major depression in a national community sample: The National Comorbidity Survey. Am. J. Psychiatry 1994, 151, 979-986.
27. Ciaramella, A., Poli, P., Assessment of depression among cancer patients: The role of pain, cancer type and treatment. Psycho-Oncology 2001, 10, 156-165.
28. Medical Letter, Drugs of choice for cancer chemotherapy. Med Lett 1993, 35, 43-50.
29. Newport, D. J., Nemeroff, C. B., Assessment and treatment of depression in the cancer patient. J. Psychosom. Res. 1998, 45, 215-237.
30. Passik, S. D., Breitbart, W. S., Depression in patients with pancreatic carcinoma. Diagnostic and treatment issues. Cancer 1996, 8, 615-626.
31. Carney, C. P., Jones, L., Woolson, R. F., Noyes, R. Jr., Doebbeling, B. N., Relationship between depression and pancreatic cancer in the general population. Psychosom. Med. 2003, 65, 884-888.
32. Fras, I., Litin, E. M., Pearson, J. S., Comparison of psychiatric symptoms in carcinoma of the pancreas with those in some other intra-abdominal neoplasms. Am. J. Psychiatry 1967, 123, 1553-1562.
33. Medical Letter, Drugs that cause psychiatric symptoms. Med. Lett. 1993, 35, 65-70.
34. Plumb, M. M., Holland, J. C., Comparative studies of psychological function in patients with advanced cancer-II, Interviewer-rated current and past psychological symptoms. Psychosom. Med. 1981, 43, 243-254.
35. Spiegel, D., Sand, S., Koopman, C., Pain and depression in patients with cancer. Cancer 1994, 74, 2570-2578.
36. Kathol, R. G., Mutgi, A., Williams, J., Clamon, G., Noyes, R. Jr., Diagnosis of major depression in cancer patients according to four sets of criteria. Am. J. Psychiatry 1990, 147, 1021-1024.
37. Schroevers, M. J., Ranchor, A. V., Sanderman, R., The role of social support and self-esteem in the presence and course of depressive symptoms: A comparison of cancer patients and individuals from the general population. Soc. Sci. Med. 2003, 57, 375-385.
38. Morris, T., Greer, H. S., White, P., Psychological and social adjustment to mastectomy: A two-year follow-up study. Cancer 1977, 40, 2381-2387.
39. Kessler, R. C., McGonagle, K. A., Swartz, M., Blazer, D. G., Nelson, C. B., Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. J. Affect Disord. 1993, 29, 85-96.
40. DeFlorio, M. L., Massie, M. J., Review of depression in cancer: Gender differences. Depression 1995, 3, 66-80.
41. Baron, R. M., Kenny, D. A., The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. J. Pers. Soc. Psychol. 1986, 51, 1173-1182.
42. McDaniel, J. S., Nemeroff, C. B., Depression in the cancer patient: Diagnostic, biological, and treatment aspects. In: Chapman, C. R., Foley, K. M. (Eds.), Current and Emerging Issues in Cancer Pain: Research and Practice. New York: Raven Press, 1993, 1-19.
43. 3H]paroxetine binding with the 5-HT transporter in brain and platelets: Relevance to studies in depression. J. Recept. Res. 1987, 7, 499-521.
44. 3H]imipramine binding in depressed patients and its circadian variations in healthy controls. J. Affect Disord. 1986, 11, 207-212.
45. 3H]paroxetine binding sites in platelets from depressed patients. J. Affect Disord. 1999, 52, 225-233.
46. 3H]imi-pramine binding: A state-dependent marker in depression. Neur. Psychopharmacol. 1984, 8, 737-741.
47. 2 receptors in human platelets via a mechanism involving protein kinase C. J. Pharmacol. Exp. Ther. 1990, 255, 305-311.
48. Uchitomi, Y., Kugaya, A., Akechi, T., et al., Three sets of diagnostic criteria for major depression and correlations with serotonin-induced platelet calcium mobilization in cancer patients. Psychopharmacology 2001, 153, 244-248.
49. Keegan, D., Bowen, R. C., Blackshaw, S., et al., A comparison of fluoxetine and amitriptyline in the treatment of major depression. Int. Clin. Psychopharmacol. 1991, 6, 117-124.
50. Nielsen, B. M., Behnke, K., Arup, p., et al., A comparison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder. Acta Psychiatr. Scand. 1993, 87, 269-272.
51. Stark, p., Hardison, C. D., A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. J. Clin. Psychiatry 1985, 46, 53-58.
52. Green, A. I., Austin, C. p., Psychopathology of pancreatic cancer. A psychobiologic probe. Psychosomatics 1993, 34, 208-221.
53. Kupfer, D. J., Sleep research in depressive illness: Clinical implications-a tasting menu. Biol. Psychiatry 1995, 38, 391-403.
54. Lauer, C. J., Riemann, D., Wiegand, M., Berger, M., From early to late adulthood changes in EEG sleep of depressed patients and healthy volunteers. Biol. Psychiatry 1991, 29, 979-993.
55. Spiker, D. G., Coble, p., Cofsky, J., Foster, F. G., Kupfer, D. J., EEG sleep and severity of depression. Biol. Psychiatry 1978, 13, 485-488.
56. Sheline, Y. I., Neuroimaging studies of mood disorder effects on the brain. Biol. Psychiatry 2003, 54, 338-352.
57. Drevets, W. C., Price, J. L., Simpson, J. R. Jr., et al., Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997, 386, 824-827.
58. Krishnan, K. R., McDonald, W. M., Escalona, p. R., et al., Magnetic resonance imaging of the caudate nuclei in depression: Preliminary observations. Arch. Gen. Psychiatry 1992, 49, 553-557.
59. Miguel-Hidalgo, J. J., Rajkowska, G., Morphological brain changes in depression: Can antidepressants reverse them? CNS Drugs 2002, 16, 361-372.
60. Plotsky, p. M., Owens, M. J., Nemeroff, C. B., Psychoneuroendocrinology of depression: Hypothalamic-pituitary-adrenal axis. Psychiatr. Clin. North Am. 1998, 21, 293-307.
61. Raison, C. L., Miller, A. H., When not enough is too much: The role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am. J. Psychiatry 2003, 160, 1554-1565.
62. Evans, D. L., McCartney, C. F., Nemeroff, C. B., et al., Depression in women treated for gynecological cancer: Clinical and neuroendocrine assessment. Am. J. Psychiatry 1986, 143, 447-452.
63. Evans, D. L., Burnett, G. B., Nemeroff, C. B., The dexamethasone suppression test in the clinical setting. Am. J. Psychiatry 1983, 140, 586-589.
64. Evans, E. L., Nemeroff, C. B., The clinical use of the dexamethasone suppression test in DSM-III affective disorders: Correlation with the severe depressive subtypes of melancholia and psychosis. J. Psychiatr. Res. 1987, 21, 185-194.
65. Joffe, R. T., Rubinow, D. R., Denicoff, K. D., Maher, M., Sindelau, W. F., Depression and carcinoma of the pancreas. Gen. Hosp. Psychiatry 1986, 8, 241-245.
66. Anisman, H., Merali, Z., Cytokines, stress, and depressive illness. Brain Behav. Immun. 2002, 16, 513-524.
67. Capuron, L., Dantzer, R., Cytokines and depression: The need for a new paradigm. Brain Behav. Immun. 2003, 17, S119-S124.
68. Cleeland, C. S., Bennett, G. J., Dantzer, R., et al., Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 2003, 97, 2919-2925.
69. Besedovsky, H. O., del Rey, A., Immune-neuro-endocrine interactions: Facts and hypotheses. Endocr. Rev. 1996, 17, 64-102.
70. Zaks-Zilberman, M., Zaks, T. Z., Vogel, S. N., Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. Cytokine 2001, 15, 156-165.
71. Dantzer, R., Cytokine-induced sickness behavior: Where do we stand? Brain Behav. Immun. 2001, 15, 7-24.
72. Capuron, L., Ravaud, A., Gualde, N., et al., Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 2001, 26, 797-808.
73. Kristiansson, M., Saraste, L., Soop, M., Sundqvist, K. G., Thorne, A., Diminished interleukin-6 and C-reactive protein responses to laparoscopic versus open cholecystectomy. Acta Anaesthesiol. Scand. 1999, 43, 146-152.
74. Musselman, D. L., Lawson, D. H., Gumnick, J. F., et al., Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 2001, 344, 961-966.
75. Musselman, D. L., Miller, A. H., Porter, M. R., Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: Preliminary findings. Am. J. Psychiatry 2001, 158, 1252-1257.
76. Kent, S., Bluthe, R. M., Kelley, K. W., Dantzer, R., Sickness behavior as a new target for drug development. Trends Pharmacol. Sci. 1992, 13, 24-28.
77. Miller, A. H., Cytokines and sickness behavior: Implications for cancer care and control. Brain Behav. Immun. 2003, 17, S132-S134.
78. American Psychiatric Association, Practice Guidelines for the Treatment of Patients with Major Depressive Disorder, 2nd ed. Arlington, VA: American Psychiatric Publishing, Inc., 2000.
79. The National Comprehensive Cancer Network, Distress Management Clinical Practice Guidelines in Oncology, version 1.2003. (Accessed December 1, 2003, at http://www.nccn.org/physician_gls/index.html. To view the most recent and complete version of the Guideline, go to http://www.nccn.org.)
80. Pirl, W. F., Roth, A. J., Diagnosis and treatment of depression in cancer patients. Oncology 1999, 13, 1293-1301.
81. DeVane, C. L., Differential pharmacology of newer antidepressants. J. Clin. Psychiatry 1998, 59 (suppl 20), 85-93.
82. Schwartz, L., Lander, M., Chochinov, H. M., Current management of depression in cancer patients. Oncology 2002, 16, 1102-1115.
83. Kissane, D. W., Bloch, S., Smith, G. C., et al., Cognitive-existential group psychotherapy for women with primary breast cancer: A randomized controlled trial. Psycho-oncology 2003, 12, 532-546.
84. Beale, M. D., Kellner, C. H., Parsons, P. J., ECT for the treatment of mood disorders in cancer patients. Convuls. Ther. 1997, 13, 222-226.